Professor Christophe Massard

Professor Christophe Massard is Head of the Department of Therapeutic Innovation and Early Trials (DITEP) and leads the clinical research platform. He obtained his medical degree in 2006 from the University of Paris-Sud, with a specialisation (DES) in medical oncology, following a residency in the Paris hospital system. He continued his training with a postdoctoral fellowship from 2008 to 2010 in Dr Debono’s team, focusing on innovative therapies and the study of circulating tumour cells in prostate cancer. In 2013, he was awarded a PhD in science from the University of Paris-Sud for his research on circulating tumour cells in advanced cancers.

He served as a university hospital consultant at Gustave Roussy and was appointed physician within a French Comprehensive Cancer Centre (CLCC) in November 2011. He then held successive leadership positions at Gustave Roussy :

• Head of the Early Phase Trials Unit (SITEP) from 2013 to 2017,
• Chair of the Early Phase Clinical Trials Committee from 2015 to September 2017,
• Head of the Department of Therapeutic Innovation and Early Trials (DITEP) from September 2017 to June 2021.

He resumed leadership of the DITEP in January 2024.

A recognised expert in early-phase oncology trials, Professor Massard’s areas of expertise include targeted therapies, immunotherapy, antibody-drug conjugates, and genitourinary cancers. He has served as Principal Investigator in over 50 phase I trials, as well as several phase II and phase III studies. He has been actively involved in key precision medicine programmes at Gustave Roussy, such as MOSCATO, MATCH-R and UNLOCK.

Professor Massard is a member of the European Society for Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), and the American Association for Cancer Research (AACR). He is also co-founder of the French association SCOPP, which aims to promote France’s appeal in early-phase oncology clinical research.

He serves on the editorial boards of Annals of Oncology and Investigational New Drugs, and has been the Director of the European course on clinical research, MCCR, since 2025.